Compass Therapeutics (NASDAQ:CMPX) Trading Down 3.9% - Time to Sell?

Key Points

• Compass Therapeutics' share price declined by 3.9% to $4.08, with trading volume falling 50% below the average session volume.
• Analysts maintain a Moderate Buy consensus rating for Compass Therapeutics, with an average target price of $13.10, despite one analyst issuing a Sell rating.
• The company reported a loss of $0.14 per share in its last earnings report, slightly missing analysts' expectations and projecting a negative earnings per share for the current fiscal year.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report)'s share price fell 3.9% during trading on Monday . The company traded as low as $4.07 and last traded at $4.08. 714,028 shares were traded during trading, a decline of 50% from the average session volume of 1,418,965 shares. The stock had previously closed at $4.24.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CMPX. D. Boral Capital reissued a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday, August 12th. Guggenheim boosted their target price on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Tuesday, August 12th. Lifesci Capital began coverage on shares of Compass Therapeutics in a research note on Monday, October 6th. They issued an "outperform" rating and a $10.00 target price on the stock. Compass Point set a $10.00 target price on shares of Compass Therapeutics in a research note on Monday, October 6th. Finally, Raymond James Financial upgraded shares of Compass Therapeutics to an "outperform" rating and set a $9.00 target price on the stock in a research note on Tuesday, July 1st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $13.10.

Compass Therapeutics Price Performance

The stock has a market cap of $595.30 million, a P/E ratio of -9.54 and a beta of 1.48. The firm's fifty day moving average price is $3.36 and its two-hundred day moving average price is $2.66.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). On average, research analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

A number of large investors have recently added to or reduced their stakes in CMPX. Creative Planning bought a new position in Compass Therapeutics during the 2nd quarter worth approximately $30,000. Strs Ohio bought a new stake in Compass Therapeutics during the 1st quarter valued at $34,000. Birchview Capital LP purchased a new stake in Compass Therapeutics during the 1st quarter valued at $46,000. Walleye Trading LLC purchased a new stake in Compass Therapeutics during the 1st quarter valued at $48,000. Finally, Vontobel Holding Ltd. bought a new stake in Compass Therapeutics in the 1st quarter worth $57,000. Hedge funds and other institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.